NAVAMEDIC (NAVA.OL) Stock Fundamental Analysis
OSL:NAVA - Euronext Oslo - NO0010205966 - Common Stock - Currency: NOK
NAVA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 50 industry peers in the Pharmaceuticals industry. While NAVA seems to be doing ok healthwise, there are quite some concerns on its profitability. NAVA is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
NAVA had negative earnings in the past year.
In the past year NAVA had a positive cash flow from operations.
In multiple years NAVA reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: NAVA reported negative operating cash flow in multiple years.
1.2 Ratios
NAVA has a Return On Assets of -1.17%. This is in the lower half of the industry: NAVA underperforms 66.00% of its industry peers.
NAVA has a Return On Equity of -2.53%. This is in the lower half of the industry: NAVA underperforms 66.00% of its industry peers.
NAVA's Return On Invested Capital of 9.30% is in line compared to the rest of the industry. NAVA outperforms 58.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for NAVA is below the industry average of 14.75%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.17% | ||
| ROE | -2.53% | ||
| ROIC | 9.3% |
ROA(3y)1.27%
ROA(5y)-0.47%
ROE(3y)1.61%
ROE(5y)-1.5%
ROIC(3y)10.14%
ROIC(5y)N/A
1.3 Margins
NAVA has a Operating Margin (7.42%) which is comparable to the rest of the industry.
NAVA's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 39.30%, NAVA is doing worse than 78.00% of the companies in the same industry.
NAVA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.42% | ||
| PM (TTM) | N/A | ||
| GM | 39.3% |
OM growth 3Y13.14%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5Y5.2%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so NAVA is still creating some value.
Compared to 1 year ago, NAVA has more shares outstanding
NAVA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for NAVA has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.53 indicates that NAVA is not a great score, but indicates only limited risk for bankruptcy at the moment.
NAVA's Altman-Z score of 2.53 is in line compared to the rest of the industry. NAVA outperforms 48.00% of its industry peers.
NAVA has a debt to FCF ratio of 3.29. This is a good value and a sign of high solvency as NAVA would need 3.29 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 3.29, NAVA is doing good in the industry, outperforming 64.00% of the companies in the same industry.
NAVA has a Debt/Equity ratio of 0.37. This is a healthy value indicating a solid balance between debt and equity.
NAVA's Debt to Equity ratio of 0.37 is fine compared to the rest of the industry. NAVA outperforms 64.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.37 | ||
| Debt/FCF | 3.29 | ||
| Altman-Z | 2.53 |
ROIC/WACC1.23
WACC7.57%
2.3 Liquidity
NAVA has a Current Ratio of 1.42. This is a normal value and indicates that NAVA is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of NAVA (1.42) is comparable to the rest of the industry.
A Quick Ratio of 0.84 indicates that NAVA may have some problems paying its short term obligations.
NAVA has a worse Quick ratio (0.84) than 62.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.42 | ||
| Quick Ratio | 0.84 |
3. Growth
3.1 Past
NAVA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.58%.
NAVA shows a small growth in Revenue. In the last year, the Revenue has grown by 6.15%.
Measured over the past years, NAVA shows a very strong growth in Revenue. The Revenue has been growing by 23.00% on average per year.
EPS 1Y (TTM)-5.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-362.72%
Revenue 1Y (TTM)6.15%
Revenue growth 3Y24.05%
Revenue growth 5Y23%
Sales Q2Q%9.23%
3.2 Future
NAVA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.84% yearly.
Based on estimates for the next years, NAVA will show a quite strong growth in Revenue. The Revenue will grow by 16.69% on average per year.
EPS Next Y-43.8%
EPS Next 2Y38.37%
EPS Next 3Y40.99%
EPS Next 5Y30.84%
Revenue Next Year9.98%
Revenue Next 2Y10.59%
Revenue Next 3Y10.61%
Revenue Next 5Y16.69%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NAVA. In the last year negative earnings were reported.
NAVA is valuated reasonably with a Price/Forward Earnings ratio of 8.89.
NAVA's Price/Forward Earnings ratio is rather cheap when compared to the industry. NAVA is cheaper than 82.00% of the companies in the same industry.
NAVA is valuated cheaply when we compare the Price/Forward Earnings ratio to 21.90, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 8.89 |
4.2 Price Multiples
NAVA's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. NAVA is cheaper than 92.00% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of NAVA indicates a rather cheap valuation: NAVA is cheaper than 88.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.98 | ||
| EV/EBITDA | 5.57 |
4.3 Compensation for Growth
NAVA's earnings are expected to grow with 40.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.37%
EPS Next 3Y40.99%
5. Dividend
5.1 Amount
No dividends for NAVA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OSL:NAVA (7/3/2025, 7:00:00 PM)
22.4
+0.3 (+1.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners32.09%
Inst Owner ChangeN/A
Ins Owners16.59%
Ins Owner ChangeN/A
Market Cap395.58M
Analysts82.86
Price Target36.72 (63.93%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-9.93%
Min Revenue beat(2)-17.93%
Max Revenue beat(2)-1.92%
Revenue beat(4)1
Avg Revenue beat(4)-6.45%
Min Revenue beat(4)-17.93%
Max Revenue beat(4)3.23%
Revenue beat(8)3
Avg Revenue beat(8)-0.95%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.5%
PT rev (3m)5.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.97%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 8.89 | ||
| P/S | 0.74 | ||
| P/FCF | 10.98 | ||
| P/OCF | 10.05 | ||
| P/B | 1.83 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.57 |
EPS(TTM)-0.71
EYN/A
EPS(NY)2.52
Fwd EY11.25%
FCF(TTM)2.04
FCFY9.11%
OCF(TTM)2.23
OCFY9.95%
SpS30.09
BVpS12.27
TBVpS-1.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.17% | ||
| ROE | -2.53% | ||
| ROCE | 12.08% | ||
| ROIC | 9.3% | ||
| ROICexc | 11.12% | ||
| ROICexgc | 140.87% | ||
| OM | 7.42% | ||
| PM (TTM) | N/A | ||
| GM | 39.3% | ||
| FCFM | 6.78% |
ROA(3y)1.27%
ROA(5y)-0.47%
ROE(3y)1.61%
ROE(5y)-1.5%
ROIC(3y)10.14%
ROIC(5y)N/A
ROICexc(3y)12.6%
ROICexc(5y)N/A
ROICexgc(3y)98.8%
ROICexgc(5y)N/A
ROCE(3y)13.17%
ROCE(5y)N/A
ROICexcg growth 3Y90.11%
ROICexcg growth 5YN/A
ROICexc growth 3Y12.82%
ROICexc growth 5YN/A
OM growth 3Y13.14%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5Y5.2%
F-Score6
Asset Turnover1.14
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.37 | ||
| Debt/FCF | 3.29 | ||
| Debt/EBITDA | 1.01 | ||
| Cap/Depr | 8.24% | ||
| Cap/Sales | 0.63% | ||
| Interest Coverage | 5.07 | ||
| Cash Conversion | 49.31% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.42 | ||
| Quick Ratio | 0.84 | ||
| Altman-Z | 2.53 |
F-Score6
WACC7.57%
ROIC/WACC1.23
Cap/Depr(3y)19.25%
Cap/Depr(5y)40.99%
Cap/Sales(3y)0.55%
Cap/Sales(5y)0.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-362.72%
EPS Next Y-43.8%
EPS Next 2Y38.37%
EPS Next 3Y40.99%
EPS Next 5Y30.84%
Revenue 1Y (TTM)6.15%
Revenue growth 3Y24.05%
Revenue growth 5Y23%
Sales Q2Q%9.23%
Revenue Next Year9.98%
Revenue Next 2Y10.59%
Revenue Next 3Y10.61%
Revenue Next 5Y16.69%
EBIT growth 1Y67.35%
EBIT growth 3Y40.35%
EBIT growth 5YN/A
EBIT Next Year22.79%
EBIT Next 3Y27.28%
EBIT Next 5Y26.96%
FCF growth 1Y189721%
FCF growth 3YN/A
FCF growth 5Y24.61%
OCF growth 1Y1706.01%
OCF growth 3YN/A
OCF growth 5Y25.36%